Current Headlines

  1. Vaccine & Gene Therapy Institute, TapImmune Partner On Cancer Vaccines
    11/21/2014

    The Vaccine & Gene Therapy Institute of Florida (VGTI), a non-profit research institute, and TapImmune have formed a partnership to develop TapImmune’s cancer vaccines.

  2. Tufts Report Puts Cost Of R&D At $2.6B Per New Drug
    11/21/2014

    It’s not a secret that developing a safe and effective drug is a long, arduous, and expensive process. A new study released this week estimates the approximate numbers. According to Tufts Center for the Study of Drug Development, the cost of developing a new drug from discovery to market is about $2.6 billion and is over a decade’s worth of work.

  3. Roche, Inovio End Pact On Prostate Cancer Drug
    11/21/2014

    Inovio Pharmaceuticals announced that it has ended its agreement with biotech giant Roche to jointly develop Inovio’s INO-5150 as immunotherapy for prostate cancer.

  4. Global Coalition Formed For Accelerating Drug Development For Brain Diseases
    11/21/2014

    A new coalition of nine charities and funding bodies has been formed to revive the development of promising drug candidates for neurodegenerative brain diseases — an initiative jumpstarted with roughly £30 million ($47 million) in funding.

  5. Researchers Discover Potential Drug For Rare Pediatric Brain Tumor
    11/20/2014

    Researchers at Northwestern Medicine have discovered a new potential drug that shows promise in treating a rare and incurable form of brain tumor in children. 

  6. Merck JV, Hilleman Laboratories Form Collaboration To Fast-Track Oral Cholera Vaccine
    11/20/2014

    Hilleman Laboratories, a vaccine developer and manufacturer based in New Delhi, has signed a Memorandum of Understanding (MoU) with ICD DR, B and Incepta Vaccine to expedite clinical trials and eventual marketing for a new oral cholera vaccine, Business Standard reports.

  7. Researchers Convert Skin Cells To Replace HD-Damaged Brain Cells
    11/20/2014

    A team of researchers at the Washington University School of Medicine in St. Louis reported that they have discovered a way to directly convert human skin cells into a type of brain cell that has been damaged by Huntington’s disease.

  8. Celgene Wins Rights To Moffitt’s Investigational MDS Therapy
    11/20/2014

    The Moffitt Cancer Center announced Monday that it has entered an exclusive licensing agreement with Celgene Corporation, which gives Celgene the exclusive rights to its novel, investigational therapy for Myelodysplastic Syndromes (MDS).

  9. Pfizer Links With Merck KGaA In Immuno-Oncology Mega Deal
    11/19/2014

    Pfizer announced that it has signed up with German firm Merck KGaA to co-develop and market an investigational anti-PD-L1 treatment for several types of cancer.

  10. ADC Market To Reach $3 Billion By 2018, Report Finds
    11/19/2014

    According to a new report from Research and Markets, Antibody drug conjugates (ADCs) are so effective against cancer, that the global market for the agents will reach $3 billion by 2018.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.